Brookfield Corp’s Neurocrine Biosciences NBIX Stock Holding History

Brookfield Corp’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-66,243	Closed	-$6.21M	–	704
2022 Q1	$6.21M	Buy	+66,243	New	+$5.61M	0.02%	227

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Brookfield Corp's NBIX Position: Q2 2022 in Review

Brookfield Corp sold out of Neurocrine Biosciences (NBIX) in Q2 2022, closing a stake of 66,243 shares — an estimated $6.21M sold.

Brookfield Corp first reported a position in NBIX in Q1 2022 and held it in 1 quarter. The position peaked at $6.21M in Q1 2022. 438 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

Brookfield Corp reported no remaining Neurocrine Biosciences position as of Q2 2022 after selling out during the quarter.
Brookfield Corp sold 66,243 Neurocrine Biosciences shares in Q2 2022, an estimated $6.21M.
Brookfield Corp first reported a position in Neurocrine Biosciences in Q1 2022 and held it in 1 quarter.
Brookfield Corp's Neurocrine Biosciences position peaked at $6.21M in Q1 2022.
438 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Brookfield Corp's 13F filing for Q2 2022, filed 15 Aug 2022.